Genetic Profiling of BRAF Inhibitor–Induced Keratoacanthomas Reveals No Induction of MAP Kinase Pathway Expression
- 1 March 2013
- journal article
- Published by Elsevier BV in Journal of Investigative Dermatology
- Vol. 133 (3), 830-833
- https://doi.org/10.1038/jid.2012.353
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- RAS Mutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF InhibitorsJournal of Clinical Oncology, 2012
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E MutationThe New England Journal of Medicine, 2011
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationNature, 2010
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaNature, 2010
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaThe New England Journal of Medicine, 2010
- The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective mannerProceedings of the National Academy of Sciences of the United States of America, 2010
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAFCell, 2010
- Identification of direct transcriptional targets of V600EBRAF/MEK signalling in melanomaPigment Cell & Melanoma Research, 2009
- Are Keratoacanthomas Variants of Squamous Cell Carcinomas? A Comparison of Chromosomal Aberrations by Comparative Genomic HybridizationJournal of Investigative Dermatology, 2006
- Differentiating Squamous Cell Carcinoma from Keratoacanthoma Using Histopathological CriteriaDermatology, 1999